The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?

The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]

Bibliographic Details

Published in:	Current oncology (Toronto) 2015-04, Vol.22 (2), p.77-79
Main Authors:	Younis, T, Groom, A
Format:	Article
Language:	English
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!